Liver transplant for hepatocellular carcinoma: Experience in a Saudi population

Experimental and Clinical Transplantation

Volumn 6, Issue 1, 2008, Pages 14-24

  Allam, Naglaa ^a,d   Khalaf, Hatem ^b   Fagih, Mosa ^c   Al Sebayel, Mohamed ^c  

^a MENOUFIA UNIVERSITY   (Egypt)

^b Suez Canal University Faculty of Medicine   (Egypt)

^c KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^d NONE   (Egypt)

Author keywords

Overall survival; Pretransplant imaging; Tumor biology; Tumor recurrence; Vascular invasion

Indexed keywords

ALCOHOL; ALPHA FETOPROTEIN;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; ARTICLE; BILE DUCT CARCINOMA; CADAVER DONOR; CANCER GRADING; CANCER INVASION; CANCER MORTALITY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DEATH; DISEASE FREE SURVIVAL; EXPLANT; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEPATOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INCIDENTAL FINDING; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; MALE; MEDICAL RECORD REVIEW; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE CARE; PROGNOSIS; PROTEIN BLOOD LEVEL; RADIOFREQUENCY ABLATION; RECURRENCE RISK; RISK FACTOR; SAUDI ARABIA; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE; TUMOR VOLUME; BILE DUCT TUMOR; CADAVER; INTRAHEPATIC BILE DUCT; LIVER TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PRESCHOOL CHILD; STATISTICS;

ADOLESCENT; ADULT; ALPHA-FETOPROTEINS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CADAVER; CARCINOMA, HEPATOCELLULAR; CHILD; CHILD, PRESCHOOL; CHOLANGIOCARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SAUDI ARABIA; SURVIVAL RATE;

EID: 46049099226     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127(5 suppl 1):S27-S34.
2. Madani TA. Hepatitis C virus infections reported in Saudi Arabia over 11 years of surveillance. Ann Saudi Med. 2007;27(3):191-194.
3. Abdo AA, Al-Jarallah BM, Sanai FM, et al. Hepatitis B genotypes: relation to clinical outcome in patients with chronic hepatitis B in Saudi Arabia. World J Gastroenterol. 2006 Nov 21; 12(43):7019-7024.
4. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35(3):519-524.
5. Hwang S, Lee SG, Joh JW, Suh KS, Kim DG. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. Liver Transpl. 2005; 11(10): 1265-1272.
6. Kawasaki S. Living-donor liver transplantation for hepatocellular carcinoma. Hepatogastroenterology. 2002;49(43):53-55.
7. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693-699.
8. Yang SH, Suh KS, Lee HW, et al, A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery. 2007;141(5):598-609.
9. Taketomi A, Soejima Y, Yoshizumi T, Uchiyama H, Maehara Y. Living donor liver transplantation for the patient with helpatocellular carcinoma [in Japanese]. Gan To Kagaku Ryoho. 2004;31(13):2118-2121.
10. Todo S, Furukawa H; Japanese Study Group on Organ Transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg. 2004;240(3):451-459; discussion 459-461.
11. Lo CM. Complications and long-term outcome of living liver donors: a survey of 1,508 cases in five Asian centers. Transplantation. 2003;75(suppl 3):S12-S15.
12. Moon DB, Lee SG, Adult-to-adult living donor liver transplantation at the Asan Medical Center. Yonsei Med J. 2004;45(6):1162-1168.
13. Umeshita K, Fujiwara K, Kiyosawa K, et al. Operative morbidity of living liver donors in Japan. Lancet. 2003;362(9385):687-690.
14. Shimoda M, Ghobrial RM, Carmody IC, et al. Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C. Liver Transpl. 2004; 10(12):1478-1486.
15. Regalia E, Fassati LR, Valente U, et al. Pattern and management of recurrent hepatocellular carcinoma after live; transplantation. J Hepatobiliary Pancreat Surg. 1998;5(1):29-34.
16. Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl. 2005; 11(9):1086-1092.
17. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria With the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl. 2002;8(9):765-774.
18. Yang SH, Suh KS, Lee HW, et al. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery. 2007; 141(5):598-609.
19. Sotiropoulos GC, Malagó M, Molmenti E, et al. Liver transplantation for hepatocellular carcinoma in cirrhosis: is clinical tumor classification before transplantation realistic? Transplantation. 2005;79(4):483-487.
20. Libbrecht L, Bielen D, Verslype C, et al. Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl. 2002;8(9):749-761.
21. Choi SH, Lee HH, Lee DS, et al. Clinicopathological features of incidental hepatocellular carcinoma in liver transplantation. Transplant Proc. 2004;36(8):2293-2294.
22. Ravaioli M, Grazi GL, Ercolani G, et al. Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. Transplantation. 2004;78(12):1780-1786.
23. Parfitt JR, Marotta P, Alghamdi M, et al. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl. 2007; 13(4):543-551.
24. Iwatsuki S, Dvorchik I, Marsh JW, et al. Liver transplantation for hepatocellular carcinoma: a proposal of a prognostic scoring system. J Am Coll Surg. 2000;191(4):389-394.
25. Marsh JW, Dvorchik I, Bonham CA, Iwatsuki S. Is the pathologic TNM staging system for patients with hepatoma predictive of outcome? Cancer. 2000;88(3):538-543.
26. Jonas S, Bechstein WO, Steinmüller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33(5):1080-1086.
27. Shah SA, Greig PD, Gallinger S, et al, Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg. 2006;202(2):275-283.
28. Tamura S, Kato T, Berho M, et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg. 2001;136(1):25-30; discussion 31.
29. Lo CM, Fan ST, Liu CL, Chan SC, Ng IO, Wong J. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg. 2007;94(1):78-86.
30. Hemming AW, Cattral MS, Reed AI, Van Der Werf WJ, Greig PD, Howard RJ. Liver transplantation for hepatocellular carcinoma. Ann Surg. 2001;233(5):652-659.
31. Haberal M, Emiroglu R, Karakayali H, et al. Expanded criteria for hepatocellular carcinoma and liver transplantation. Int Surg. 2007;92(2):110-115.
32. Jarnagin WR, Weber S, Tickoo SK, et al. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer. 2002;94(7):2040-2046.
33. Koh KC, Lee H, Choi MS, et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg. 2005; 189(1):120-125.
34. Taguchi J, Nakashima O, Tanaka M, Hisaka T, Takazawa T, Kojiro M. A clinicopathological study on combined hepatocellular and cholangiocarcinoma. J Gastroenterol Hepatol. 1996; 11(8):758-764.
35. Lee CC, Wu CY, Chen JT, Chen GH. Comparing combined hepatocellular-cholangiocarcinoma and cholangiocarcinoma: a clinico-pathological study. Hepatogastroenterology. 2002;49(48):1487-1490.
36. Wakasa T, Wakasa K, Shutou T, et al. A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma. Hepatogastroenterology. 2007;54(74):508-513.
37. Yano Y, Yamamoto J, Kosuge T, et al. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Jpn J Clin Oncol. 2003;33(6):283-287.
38. Sanada Y, Shiozaki S, Aoki H, Takakura N, Yoshida K, Yamaguchi Y. A clinical study of 11 cases of combined hepatocellular-cholangiocarcinoma Assessment of enhancement patterns on dynamics computed tomography before resection. Hepatol Res. 2005;32(3):185-195.
39. Lin G, Toh CH, Wu RC, et al. Combined hepatocellular cholangiocarcinoma: prognostic factors investigated by computed tomography/magnetic resonance imaging. Int J Clin Pract. 2007 May 30; [Epub ahead of print]